Developing a CAR T cell therapy for solid tumors is particularly challenging because the therapy needs to first reach the solid tumor and then survive in a harsh microenvironment that is filled with cancer cells and other cells that prevent attack by the CART cells. But Priceman and his team h...
Of side effects of CAR-T cell therapy, 20 of the 24 patients—83 percent—experienced cytokine release syndrome (grade 1-2, 18 patients; grade 4, one patient; grade 5, one patient) and 8 patients (33 percent) developed neurotoxicity (grade 3, five patients; grade 5, one patient). For...
Cancer immunotherapy has become a major treatment option in recent years. One of the most promising approaches is Chimeric antigen receptor (CAR)-T cell therapy, which involves engineering T cells to target specific cancer cells. However, CAR-T cell therapy can also have some adverse side effect...
Although CD19-CAR T cell therapy has already proven to successfully reduce tumor burden in cancer patients, further engineering is needed to enhance safety, specificity, and efficacy of this novel cellular immunotherapy. Various clinical trials reported severe side effects, such as neurotoxicity, on-...
We know in AML that the target antigen expression is very heterogeneous, both inter- and intra-individuals. Even patients have different clones with different expression profiles of the same target antigen. So that's very...
The candidate GLPG5301 is an autologous – using a patient’s own immune cells – CAR-T therapy that targets the B-cell maturation antigen expressed in B cells in multiple myeloma. GLPG5301 is not the only CAR-T drug to cause worry over parkinsonism-related side effects. ...
Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen (BCMA) has demonstrated incredible results, leading to regulatory approval of BCMA-targeted chimeric antigen receptor (CAR)-T cell therapies in RRMM. With now two...
Nkarta’s patent families related to NKX019 clinical trial The company has 14 patent families and two of them describe a CD19 CAR. First, Nkarta filed in 2020 a patent family which details a CD19 CAR construct (WO2020/180882). This patent...
However, side effects including cytokine storm, neurotoxicity or on-target/off-tumor toxicity can be challenging to manage. Further, malignant transformation of piggyBac modified CAR-T cells was recently reported in a phase I clinical trial as a potentially life threatening event. Reliable strategies...
Significant advances have been made in chimeric antigen receptor T (CAR-T)-cell therapy for the treatment of recurrent or refractory B-cell hematologic malignancies. However, CAR-T-cell therapy has not yet achieved comparable success in the management of